Rockville, MD. Rise Therapeutics today announced that the Montgomery County Economic Development Corporation (MCEDC) Fund’s Bio Lab Pilot Project issued Rise Therapeutics funding to support its clinical GMP manufacturing infrastructure build out. This grant supports a key corporative initiative for Rise Therapeutics to expand its product development infrastructure in the microbiome space to include capabilities that enable the organization to more efficiently and cost effectively transition cutting-edge microbiome discoveries into clinically validated drug products. This MCEDC funding program supports $10 per square foot of lab fit out costs to build out wet lab space up to 5,000 square feet.

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, highlighted today a new publication in the journal Science that highlights mechanisms by which the microbiota engage host immune pathways to improve immunotherapy. The article examines recent pre-clinical studies that found that the peptidoglycan hydrolase Secrete Antigen A (SagA) is able to promote immunotherapy responses and synergize with immune checkpoint inhibitors (ICI) to drive tumor regression in animal model studies. These results support development of novel synthetic biology medicines to be used in conjunction with ICI therapy.

Rockville, MD. Rise Therapeutics today announced that Montgomery County has issued Rise Therapeutics a $25,000 Small Business Innovative Research (SBIR) grant matching award. This funding was awarded based upon Montgomery County’s SBIR/STTR Matching Grant Program and will be used to further Rise Therapeutics’ research project efforts to develop novel microbiome-based medicines,

Rockville, MD. Rise Therapeutics, a synthetic biology company developing targeted immunological-based biologics using a unique and proprietary oral delivery platform, today announced the appointment of Sathya Janardhanan, MS, as Vice President of Development and Manufacturing.

Rockville, MD. Rise Therapeutics announced today that they have received funding associated with the National Institute of Health (NIH) Commercialization Readiness Program (CRP), enabling Rise to establish in house GMP manufacturing capabilities. The NIH’s CRP assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants or contracts.

Rockville, MD. Rise Therapeutics, a synthetic biology drug development company creating targeted immunological-based biologics using a unique and proprietary oral delivery platform, is pleased to announce the expansion of their executive leadership team. Rise welcomes Christian Furlan Freguia, Ph.D., to the position of Vice President of Research.